Genetic study for uveal melanoma risk
Part of Cancer, Eyes & vision clinical trials.
This study looks for new inherited genes linked to uveal melanoma (an eye cancer). If you have this cancer and don't already have a known genetic cause, you may be able to help find new genes that affect cancer risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with uveal melanoma (newly, during treatment, or after treatment).
- You are enrolled in or have health insurance (social security).
- You do not have a known mutation in the BAP1 or MBD4 genes.
- You are willing to have your genes tested for research purposes.
- You are not pregnant or breastfeeding.
- You are not under court-ordered guardianship.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks back at past medical records of people diagnosed with uveal melanoma. It helps researchers learn about the typical course of the disease by analyzing what already happened in care.
This study follows people with high-risk uveal (eye) melanoma after their initial treatment to better understand relapse risk. It may help your care team track you more closely using scheduled visits and blood tests.
This study looks at how the BAP1 gene affects cancer risk and what cancers people develop, including within families. You may be able to join if you have a known BAP1-related mutation, a strong family cancer history, or a concerning cancer pattern linked to BAP1.
This study checks whether blood “biomarkers” (measurable signs in serum) can help diagnose metastatic uveal melanoma. If you have uveal melanoma, the study may look at how useful these blood tests are for spotting spread to other parts of the body.
This trial tests a new drug (RBP-01) given before standard treatment for uveal melanoma, a type of eye cancer. The goal is to see if the drug can shrink the tumor or improve outcomes for people who need eye removal or high-risk radiation therapy.
This trial is testing a combination of two oral medications (darovasertib and crizotinib) after standard local treatment for high-risk uveal melanoma that has not spread. The goal is to see if this treatment can reduce the risk of the cancer coming back.
Hear when a new Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.